GLP-1 Drugs Linked To Lower Breast Cancer Risk In Large Studies

Powerful GLP-1 drugs such as Ozempic and Wegovy are transforming diabetes and obesity care, and new evidence suggests they may also influence cancer risk. A trio of large observational studies now points to meaningful benefits for breast cancer incidence, progression, and survival.

The research, unveiled at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, does not prove cause and effect. However, the consistency of the findings across different patient groups and tumor types is drawing serious attention from cancer specialists worldwide.

Lower odds of breast cancer

In the first study, researchers from the University of Pennsylvania reviewed health data from more than 110,000 women aged 45 to 80 with a body mass index of at least 25. About 14 percent had a prescription for GLP-1 medications such as semaglutide or liraglutide.

Women who had ever used a GLP-1 drug were 30.5 percent less likely to be diagnosed with breast cancer than those who had not. The association held even after adjusting for age, race, ethnicity, BMI, breast density, and diabetes status, suggesting the effect may extend beyond weight loss alone.

Lead investigator Elizabeth McDonald, a breast radiologist, stressed that the findings are observational and cannot prove that GLP-1 drugs prevent cancer. Her team is planning a clinical trial to test whether these medications can directly reduce breast cancer risk in women considered to be at high risk.

Slower cancer spread in users

A second study from Cleveland Clinic analyzed more than 12,000 people with lung, breast, colorectal, or liver cancer who also had diabetes. Researchers compared outcomes in patients taking GLP-1 drugs with those using other diabetes medications.

Overall, GLP-1 use was linked to a significantly lower risk of cancer progression. Among breast cancer patients, about 10 percent of those on GLP-1 therapy experienced disease progression to a more severe stage, versus roughly 20 percent of patients taking an alternative diabetes drug.

Oncologist Mark David Orland, who led the analysis, said the pattern across four solid tumor types suggests a potential class effect. He emphasized that randomized trials are now needed to confirm whether GLP-1 drugs can slow cancer growth or alter the course of the disease.

Improved survival in breast cancer

The third study presented at ASCO examined outcomes in 137,493 people with breast cancer. Patients who received GLP-1 medications for at least three continuous months had a 6 percent higher five-year overall survival rate compared with those who did not use the drugs.

The survival advantage was modest but statistically significant, and it persisted after adjusting for key clinical factors. The authors concluded that more research is needed to determine whether this benefit stems from direct biological effects or from better weight, glucose, and blood pressure control.

Breast cancer remains one of the most common cancers, with U.S. projections for 2024 suggesting more than 320,000 new cases and about 40,000 deaths. Even small relative gains in prevention or survival could translate into thousands of lives affected each year.

Possible mechanisms beyond weight loss

GLP-1 receptor agonists mimic a gut hormone that helps regulate blood sugar, slows gastric emptying, and reduces appetite, often leading to substantial weight loss. Obesity is a known risk factor for worse breast cancer outcomes, so weight reduction is one obvious pathway through which these drugs may provide benefit.

Yet emerging laboratory and clinical research points to broader effects on inflammation, immune response, and metabolic signaling. Some studies suggest GLP-1 drugs may dampen chronic low-grade inflammation, which is implicated in tumor growth and cancer cell survival.

ASCO expert Marcin Chwistek noted that GLP-1 agents have long been recognized as more than glucose-lowering therapies. He highlighted their anti-inflammatory and immune-modulating properties and said the new data, given its size and consistency, justify large prospective randomized trials.

For now, oncologists caution that patients should not start GLP-1 drugs solely to prevent cancer, and the medications still carry side effects and face supply constraints. However, as their use expands globally, researchers will gain more real-world data on long-term cancer outcomes in people receiving these widely prescribed injections.

If future trials confirm a protective or therapeutic effect, GLP-1 drugs could become part of integrated strategies to reduce cancer risk and improve survival in high-risk groups. Until then, experts say the findings are an encouraging signal that warrants careful, rigorous follow-up.